Physician profile
William J Gray
NPI 1588666317
$3,079.95
in general payments reported to CMS, 2019-2025
25 companies · $830 in 2025
The $830 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $118 · 2022: $37.99 · 2023: $421 · 2024: $892 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $706.70 | 2019-2025 | |
| Novo Nordisk INC | $497.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $364.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $315.14 | 2019-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $213.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.34 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $126.78 | 2020-2025 | General - Vascular Intervention |
| Amgen INC. | $123.36 | 2019-2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $116.61 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Glaxosmithkline, LLC. | $82.61 | 2023-2025 | Shingrix, Arexvy, Penmenvy |
| Dexcom, INC. | $77.98 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $54.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.52 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.50 | 2024-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $26.93 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.07 | 2024 | |
| Kyowa Kirin, INC. | $21.79 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.37 | 2020 | |
| Amarin Pharma, INC. | $13.96 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.49 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $12.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.22 | 2019 | |
| Eisai INC. | $11.66 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.